Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Try the south of France.
True Dat.
Not as long as Gerald needs a paycheck.
'There be Two's.
Ain't That Special.
Unless that's the plan.
"He didn't set out to screw investors"--
We don't know that. He is compensated quite well.
That is the point. Is the value .06 or .006?
No interruption in his paychecks, though.....
More arranging the Titanic deck chairs. More paper, still no sales.
There's money being made here.....but only by newbies.
Shocked, shocked I say- AMARANTUS BIOSCIENCE : Entry into a Material Definitive Agreement (form 8-K)
Item 1.01 Entry Into a Material Definitive Agreement.
Series H Preferred Stock and Warrants
On November 13, 2015, Amarantus BioScience Holdings, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Series H SPA") with an institutional investor for the sale of 330 (including 10% OID) shares of the Company's 12% Series H Preferred Stock (the "Series H Preferred Stock") and a warrant to purchase 140,250 shares of common stock (the "RD Warrant" and together with the Series H Preferred Stock, the "Securities") in a registered direct offering (the "RD Offering"), subject to customary closing conditions. The gross proceeds to the Company from the RD Offering were $290,000. Each share of Series H Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at an initial conversion price of the lower of (i) $2.50, subject to adjustment and (ii) 75%, subject to adjustment, of the lowest volume weighted average price, or VWAP, during the fifteen (15) Trading Days immediately prior to the date a conversion notice is sent to the Company by a holder, at any time at the option of the holder.
The RD Warrant is exercisable at any time on or after the earlier to occur of (i) all shares of common stock underlying the RD Warrant are registered for resale under the Securities Act of 1933, and (ii) the date six (6) months from November 13, 2015 (the earlier to occur of (i) and (ii), the "Initial Exercise Date") and on or prior to the close of business on the five-year anniversary of the Initial Exercise Date at an exercise price of $2.00 per share.
The Securities were issued pursuant to a prospectus supplement dated November 13, 2015 filed with the Securities and Exchange Commission on November 13, 2015, in connection with a takedown from the Registration Statement on Form S-3 (File No. 333-203845), which was declared effective by the SEC on May 22, 2015.
2
© Edgar Online, source Glimpses
Ol' Peter Lynch (Fidelity Magellan)said he only buys stocks when he can clearly understand what they do. Not a bad concept.
Reverse splits are the death knell for pennies. It's the way to purge stockholders and line up new chumps.
Wash, rinse, repeat.
I think he died. I'm in his will for $20,000,000.
Naw, they're eating well, thanks to stockholders.
LOL. That "reporter" thought he speaking mandarin.
I've thought that for a while now. Lot's of graphs, circles and arrows but no interest from legitimate pharma companies.
If there was real potential, big players would be lining up. Crickets.
Gotta keep those paychecks a-comin'
The market and lack of interest by Pharma suitors says no. Lotsa big syllable press releases but no industry interest.
"yes-still alive and working to turn it around"
----
Inspiring, Electric.
Delayed quote link http://www.otcmarkets.com/stock/AMBSD/quote
Volume significant.
No volume.
Just full disclosure.
For current services performed FNMG has been compensated one thousand dollars for Amarantus Bioscience Holdings, Inc news coverage by the Company. FNMG HOLDS NO SHARES OF Amarantus Bioscience Holdings, Inc.
Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
Apr 29, 2015
OTC Disclosure & News Service
-
SAN FRANCISCO and GENEVA, April 29, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug status for MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of retinitis pigmentosa (RP). RP refers to a group of inherited diseases causing retinal degeneration often leading to blindness. The Company previously announced in December of 2014 that it also received orphan drug designation for MANF for the treatment of RP from the U.S. Food and Drug Administration (FDA).
"We are extremely pleased to have received European orphan drug status for our promising investigational product, MANF in RP," said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. "This EU orphan designation, combined with our recent U.S. orphan designation, positions MANF for an accelerated global regulatory product development pathway to address the significant unmet need in this important ophthalmologic indication."
Orphan drug designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment is available. In addition to a 10-year period of marketing exclusivity in the EU after product approval, orphan drug designation provides incentives for companies seeking protocol assistance from the EMA during the product development phase, and direct access to the centralized authorization procedure.
David A. Lowe, Ph.D., member of the Amarantus Board Directors, commented, "We believe MANF has potential as a promising potential treatment in multiple orphan ophthalmologic disorders. We intend to continue pursuing the orphan regulatory pathway for MANF as we move this program forward."
About Retinitis Pigmentosa
Retinitis pigmentosa (RP) refers to a group of inherited diseases causing retinal degeneration often leading to blindness. The retina lines the inside back wall of the eye and is responsible for capturing images from the visual field. People with RP experience a gradual decline in their vision because photoreceptor cells (rods and cones) die. Symptoms include a progressive degeneration of peripheral and night vision, as well as a reduction in color perception and central vision. Night blindness is one of the earliest and most frequent symptoms of RP.
RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40.
About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)
MANF (mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property around MANF, and is initially focusing on the development of MANF-based protein therapeutics.
MANF's lead indication is retinitis pigmentosa, and additional indications including Parkinson's disease, diabetes and Wolfram's syndrome are currently pursued. Further applications for MANF may include Alzheimer's disease, traumatic brain injury, myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF's discovery.
Need Volume
Amarantus Receives Orphan Drug Designation for MANF in Retinitis Pigmentosa
By Jason Napodano, CFA
Tuesday, December 23, 2014
http://bionapcfa.blogspot.com/2014/12/amarantus-receives-orphan-drug.html
Sierra World Equity Review
Hat in hand_Amarantus BioScience (AMBS) To partner with Roche subsidiary following statistically improvement announcement after further evaluation of MANF study forecasts Sierra World Equity Review
As posted in "The Day Shorters Room"
#148718 $AMBS Tradingstockdotbiz 07/21/14 02:05:50 PM
Good Post.
1.80 is resistance. Break that and it's blue sky to 2.40.
http://stockcharts.com/h-sc/ui?s=mnga
Huh? <scratch, scratch>
Proportion.
Never Met Him.
Thank You for taking the time to post this. It gives us a "feel" for GC's current "attitude". He's giving off a positive vibe.
SGLB ripping
Hmmmmm....... someone's interested .079